Leerink Partnrs Issues Negative Estimate for OmniAb Earnings

OmniAb, Inc. (NASDAQ:OABI - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2025 EPS estimates for shares of OmniAb in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.64) per share for the year, down from their previous forecast of ($0.63). The consensus estimate for OmniAb's current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb's Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.61) EPS.

OmniAb (NASDAQ:OABI - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. The firm had revenue of $10.80 million during the quarter, compared to the consensus estimate of $10.13 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share.

Other equities research analysts have also recently issued research reports about the company. Benchmark lowered their price target on OmniAb from $8.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, March 20th. HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of OmniAb in a research report on Wednesday, March 19th.

Remove Ads

OmniAb Stock Performance

Shares of NASDAQ:OABI traded down $0.10 on Friday, hitting $2.44. 698,011 shares of the company's stock were exchanged, compared to its average volume of 538,565. OmniAb has a 1-year low of $2.23 and a 1-year high of $5.54. The company has a market capitalization of $344.57 million, a PE ratio of -3.94 and a beta of -0.14. The firm's 50-day moving average is $3.31 and its 200 day moving average is $3.74.

Insider Activity at OmniAb

In other news, CEO Matthew W. Foehr sold 41,811 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the transaction, the chief executive officer now directly owns 3,749,639 shares in the company, valued at approximately $12,148,830.36. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Charles S. Berkman sold 25,489 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the sale, the insider now owns 343,190 shares of the company's stock, valued at approximately $1,111,935.60. This trade represents a 6.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 112,260 shares of company stock valued at $376,601 in the last three months. 8.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On OmniAb

Several large investors have recently modified their holdings of OABI. Hsbc Holdings PLC purchased a new position in OmniAb in the 4th quarter valued at $38,000. Choreo LLC purchased a new stake in shares of OmniAb in the fourth quarter valued at about $41,000. Rangeley Capital LLC purchased a new stake in shares of OmniAb in the fourth quarter valued at about $41,000. KLP Kapitalforvaltning AS acquired a new position in shares of OmniAb during the 4th quarter worth $49,000. Finally, Walleye Capital LLC purchased a new position in shares of OmniAb in the 3rd quarter valued at about $61,000. Hedge funds and other institutional investors own 72.08% of the company's stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.